Epcoritamab SC monotherapy for r/r DLBCL ≥3L (EPCORE NHL-1)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-EPCORITAMAB |
|---|
| ID | REGIMEN-EPCORITAMAB-MONO-DLBCL-3L |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-01 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Notes
First-in-class subcutaneous CD20×CD3 bispecific T-cell engager for relapsed/refractory diffuse large B-cell lymphoma after ≥2 prior lines (including patients ineligible for or relapsed after CAR-T). EPCORE NHL-1 (Thieblemont et al., J Clin Oncol 2023): in r/r LBCL ≥3L (n=157, ~39% prior CAR-T) — ORR ~63%, CR ~39%, median DOR ~12 months, median PFS ~4.4 mo, median OS not reached at primary analysis. Step-up dosing (0.16 → 0.8 → 48 mg) + cycle-1 corticosteroid prophylaxis reduce CRS to predominantly Grade 1-2 (any-grade ~50%, G≥3 ~3%). ICANS ~6% any-grade. SC route + ambulatory schedule favourable vs IV bispecifics for outpatient-heavy practices. Continuous indefinite dosing (vs 12-cycle fixed-duration glofitamab) is the principal sequencing trade-off. See REGIMEN-EPCORITAMAB-STEP-UP-DOSING for the standalone cycle-1 step-up sub-schedule. Bibliographic record SRC-EPCORE-NHL-1-THIEBLEMONT-2023 is available; clinical claim linkage requires dual clinical sign-off.
Used By
No reverse references found in the YAML corpus.